IL-2

Links to news articles on IL-2 .

Nexavar Approved in Switzerland for the Treatment of Patients with ... -- 30 Mar 2006
...of patients with advanced renal cell carcinoma (RCC), or kidney cancer, after nepherectomy and prior palliative or adjuvant therapy with cytokines (IL-2, IFN). ... Yahoo! News (press release)

Thalidomide and IL-2 Effective for Metastatic Renal Cell Carcinoma -- Mar 20, 2006
RCC. Il-2 is an agent that stimulates the immune system to fight cancer. Il-2 has been used to treat RCC for more than two decades. ... Cancer Consultants (press release),

Thalomid® and IL-2 Effective for Metastatic Renal Cell Carcinoma -- Mar 20, 2006
2 (IL-2) and Thalomid (thalidomide) results in a 52% disease control rate. The details of this study appeared in the April 1, 2006, issue of Cancer . ... Cancer Consultants (press release),

International Award Honors Discoveries In Cellular And Molecular ... -- Mar 23, 2006
...to create interferons and IL-2 in the laboratory, making recombinant cytokines available for use in clinical applications involving cancer, hepatitis and ... Medical News Today (press release),

New treatments based on T-cell stimulation possible -- Mar 3, 2006
...that was injected was specific to interleukin-2 (IL-2), a naturally occurring protein and a known immunotherapy for metastatic melanoma and renal cancer. ... In-PharmaTechnologist.com,

EpiCept Reports 2005 Operating and Financial Results -- Mar 15, 2006
Results demonstrated that subjects treated with Ceplene plus IL-2 experienced a ... into Phase I clinical studies in solid tumors and metastatic brain cancer. ... MSN Money

Biomira Inc. announces year-end results -- Mar 9, 2006
Merck has shown its strong and continued commitment to cancer vaccines and to L ... was created to fully exploit Liposomal Interleukin-2 (L-IL-2) technology that ... Yahoo! News (press release)

EpiCept Reports 2005 Operating and Financial Results -- Mar 15, 2006
Cancer: Ceplene Ceplene is EpiCept's registration-stage compound for the treatment ... and controlled Phase III trial investigating Ceplene plus IL-2 (interleukin-2 ... PR Newswire (press release),

Researchers Discover Molecule Allowing Cancer to Spread -- Mar 8, 2006
The primary treatment for patients with advanced kidney cancer is IL-2, the only FDA-approved immunotherapeutic agent to stimulate the immune system. ... eMaxHealth.com,

Do 73% of Americans Die from Just One Actual Disease -- Mar 6, 2006
...mood and sleep, reduce nervousness and chronic fatigue, fight cancer and heart disease ... cytokines, including TNF-a tumor necrosis factor alpha, IL-2 interleukin 2 ... ClickPress (press release),

Mesothelioma Treatment 101 -- Mar 2, 2006
...patients with bladder cancer). Mesothelioma cells proved susceptible to in vitro lysis by LAK cells following activation by interleukin-2 (IL-2), but patients ... Only Idol,

Patients vs. Paternalism -- Mar 6, 2006
A more recent example is aldesleukin (also known as interleukin-2, or IL-2), a drug that has offered new hope to victims of kidney cancer and malignant melanoma ... TCS Daily,

Clinical Data Evaluating CC-10004 As New Oral Therapy in Severe ... -- Mar 6, 2006
...mediators including PDE-4, TNF-alpha, interleukin-2 (IL-2), interferon-gamma, leukotrienes ... of innovative therapies for the treatment of cancer and inflammatory ... International News Service,

RhuDex successfully concludes Phase I clinical trials -- Mar 9, 2006
IL-1? , IL-2 and IFN? . ... Avidex has two key programmes leading to novel treatments in cancer, inflammation and autoimmune diseases. ... PharmaLive.com (press release),

Avidex Announces Rhudex® Successfully Completes Phase I Studies ... -- Mar 9, 2006
...the release of inflammatory cytokines such as TNF? , IL-1? , IL-2 and IFN? . ... has two key programmes leading to novel treatments in cancer, inflammation and ... WebWire (press release),

Immune Substances May Help Antibody-Based Drugs Fight Cancer -- Jan 6, 2006
For example, the researchers added human NK cells and IL-2 or IL-12 to cultures of breast-cancer cells with HER2 and coated with trastuzumab antibodies. ... DG News

Synta Pharmaceuticals to Focus on Oral Inhibitor for Crohn's ... -- Dec 29, 2005
...cell proliferation and secretion of inflammatory mediators such as IL-2. Therapies that ... Synta is developing a novel small-molecule agent for cancer, STA-9584 ... EndoNurse,

New Treatment For Kidney And Skin Cancer -- Dec 27, 2005
Dr. Gross wanted Susan to try a new treatment called, IL-2 which uses a protein ... The body's own defense against cancer and the drug goes in and find the cancer ... KLTV,

New drug combo may boost cancer treatment -- Jan 5, 2006
1 issue of the journal Cancer Research, is the first to indicate that the drug ... may work better when it is followed by injections of interleukin, IL-2 or IL-12. ... Science Daily (press release)

Immune-system boosters aid cancer drugs -- Jan 9, 2006
...found that the cancer drug Herceptin (trastuzumab) may be even more effective in fighting breast cancer when followed by injections of interleukin (IL) 2 or IL ... United Press International

Immune stimulants may help cancer patients, study shows -- Jan 9, 2006
...may work better when it is followed by injections of interleukin (IL) 2 or IL ... of an antibody that targets the protein HER2, which is present on cancer cells of ... Pharmaceutical Business Review

New Insight Into Machinery Of Immune Cells' 'tentacles' -- Jan 10, 2006
...immune system's production of a key immune cell trigger, called IL-2, in response ... the Pendergast laboratory in the Department of Pharmacology and Cancer Biology ... Medical News Today (press release),

Synta Pharmaceuticals to Focus 2006 Development on Its Oral IL-12 ... -- 23 Dec 2005
...cell proliferation and secretion of inflammatory mediators such as IL-2. Therapies that ... Synta is developing a novel small-molecule agent for cancer, STA-9584 ... PR Newswire (press release),

Zenotech to launch two bio generics in Feb, plans GDR -- Dec 20, 2005
...launch in February next two generic biological products, used in cancer therapy ... planning to launch another bio generic for oncology, Interleukin-2 (IL-2) in the ... Newindpress,

Active Biotech Reports Interim Results of ANYARA Phase I Clinical ... -- Dec 14, 2005
...to be in the therapeutic range also have had similar sustained IL-2 levels ... reported, ANYARA also effectively localizes to 5T4 positive tumors in cancer patients ... Market Wire (press release)

Phase II Study Demonstrates that ONTAK(R) Benefits Patients with ... -- Dec 14, 2005
...results of a Phase II study performed at the MD Anderson Cancer Center in ... whose tumors positively expressed the p55 (CD25) component of the IL-2 receptor, 61.5 ... Business Wire (press release),

Transgene: Clinical Pipeline Update -- Nov 29, 2005
...and radiotherapy treatment of stages IIIB and IV lung cancer, survival rates ... The sequence coding for the cytokine interleukin 2 (IL-2) is included to help ... PR Newswire (press release),

Partnership to develop new renal cancer test -- Dec 13, 2005
RCC is an aggressive cancer, with a lack of early warning signs ... infrequent responses to immunotherapy agents such as interferon alpha and interleukin (IL)-2. ... OutSourcing-Pharma.com,

2nd Phase II Trial with Trovax® in Renal Cell Carcinoma, Oxford ... -- Nov 19, 2005
2 (IL-2) in patients with metastatic renal cell carcinoma (RCC). There are now five Phase II trials ongoing with TroVax in RCC and colorectal cancer. ... Medical News Today (press release),

Mayo Clinic Researchers Discover Molecule Allowing Cancer to ... -- Nov 15, 2005
The primary treatment for patients with advanced kidney cancer is IL-2, the only FDA-approved immunotherapeutic agent to stimulate the immune system. ... AScribe

Clinical Briefs For November 2005 -- Oct 30, 2005
...should provide a clearer picture of the clinical impact of IL-2 on the course ... Researchers at the University of Minnesota Cancer Center and the National Cancer ... U.S. Medicine,

Modifying Immune System Response to Cancer Chemotherapy Could Lead ... -- Nov 2, 2005
The cancer patients in the study were assigned to one of three groups: the first group received moderate-dose IL-2 therapy; the second group received low-dose ... Kansas City infoZine,

Biomira to present at Bio-Europe 2005 -- Nov 7, 2005
...well as out-licensing opportunities: - Liposomal Interleukin-2 (L-IL-2), available through ... based liposomal vaccine program in non-small cell lung cancer (NSCLC ... PR Newswire (press release),

Biomira to present at Bio-Europe 2005 -- Nov 7, 2005
Liposomal Interleukin-2 (L-IL-2), available through ... Liposome Vaccine (L-BLP25), a MUC1-based liposomal vaccine program in non-small cell lung cancer (NSCLC). ... Yahoo! News (press release)

Mesothelioma Treatment 101 -- Oct 25, 2005
...patients with bladder cancer). Mesothelioma cells proved susceptible to in vitro lysis by LAK cells following activation by interleukin-2 (IL-2), but patients ... juiceenewsdaily,

... Go to the Article -- Nov 1, 2005
...a genetically engineered version of interleukin-2 (IL-2), a natural protein that stimulates the immune system to attack certain kinds of cancer cells. ... CancerWise

Roche and Protein Design Labs to Jointly Develop Daclizumab in ... -- Nov 1, 2005
...in diagnostics, the leading supplier of pharmaceuticals for cancer, as well ... is a humanized monoclonal antibody that blocks interleukin-2 (IL- 2) receptors and ... PharmaLive.com (press release),

More information on IL-2 from the National Cancer Institute

Biological therapy is a type of treatment that works with your immune system. It can help fight cancer or help control side effects (how your body reacts to the drugs you are taking) from other cancer treatments like chemotherapy.

What is the difference between biological therapy and chemotherapy?

Biological therapy and chemotherapy are both treatments that fight cancer. While they may seem alike, they work in different ways. Biological therapy helps your immune system fight cancer. Chemotherapy attacks the cancer cells directly.

How does biological therapy fight cancer?

Doctors are not sure how biological therapy helps your immune system fight cancer. But they think it may:

Stop or slow the growth of cancer cells.
Make it easier for your immune system to destroy, or get rid of, cancer cells.
Keep cancer from spreading to other parts of your body.